Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fit" protocol to improve the homology models of 5-HT(2A) receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT(2A) models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, K(i) = 1959, 56, and 417 nM against 5-HT(2A), 5-HT(2B), and 5-HT(2C), respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-target" 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

[1]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[2]  G. Klebe,et al.  Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.

[3]  Claudio N. Cavasotto,et al.  Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[4]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[5]  Leming Shi,et al.  Identifying Unexpected Therapeutic Targets via Chemical-Protein Interactome , 2010, PloS one.

[6]  M. Jacobson,et al.  Automated site preparation in physics‐based rescoring of receptor ligand complexes , 2009, Proteins.

[7]  B. Roth,et al.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.

[8]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[9]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[10]  D J Diller,et al.  The different strategies for designing GPCR and kinase targeted libraries. , 2004, Combinatorial chemistry & high throughput screening.

[11]  B. Shoichet,et al.  Hierarchical docking of databases of multiple ligand conformations. , 2005, Current topics in medicinal chemistry.

[12]  Narmada Thanki,et al.  CDD: a Conserved Domain Database for the functional annotation of proteins , 2010, Nucleic Acids Res..

[13]  Miles Congreve,et al.  The impact of GPCR structures on pharmacology and structure‐based drug design , 2010, British journal of pharmacology.

[14]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[15]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[16]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[17]  Richard A. Friesner,et al.  Integrated Modeling Program, Applied Chemical Theory (IMPACT) , 2005, J. Comput. Chem..

[18]  Niu Huang,et al.  Physics-Based Scoring of Protein-Ligand Complexes: Enrichment of Known Inhibitors in Large-Scale Virtual Screening , 2006, J. Chem. Inf. Model..

[19]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[20]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[21]  M. Ivarsson,et al.  Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders. , 2010, Bioorganic & medicinal chemistry letters.

[22]  Jian Wang,et al.  In Silico Elucidation of the Molecular Mechanism Defining the Adverse Effect of Selective Estrogen Receptor Modulators , 2007, PLoS Comput. Biol..

[23]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[24]  B. Matthews,et al.  A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.

[25]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[26]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[27]  Marta Filizola,et al.  Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.

[28]  M. Jacobson,et al.  Virtual screening against highly charged active sites: identifying substrates of alpha-beta barrel enzymes. , 2005, Biochemistry.

[29]  Michael M. Mysinger,et al.  Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.

[30]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[31]  Jonathan S. Mason,et al.  Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.

[32]  M. Jacobson,et al.  Molecular mechanics methods for predicting protein-ligand binding. , 2006, Physical chemistry chemical physics : PCCP.

[33]  B. Roth,et al.  Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.

[34]  W. Goddard,et al.  Computational modeling of structure-function of g protein-coupled receptors with applications for drug design. , 2010, Current medicinal chemistry.

[35]  H Weinstein,et al.  Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.

[36]  B. Roth,et al.  Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation. , 2008, Journal of medicinal chemistry.

[37]  B. Roth.  Drugs and valvular heart disease. , 2007, The New England journal of medicine.

[38]  Anat Levit,et al.  Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. , 2010, Current opinion in drug discovery & development.

[39]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[40]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[41]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[42]  M. Rowley,et al.  Current and novel approaches to the drug treatment of schizophrenia. , 2001, Journal of medicinal chemistry.

[43]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[44]  B. Roth,et al.  A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.

[45]  Matthew P Jacobson,et al.  Virtual Ligand Screening against Escherichia coli Dihydrofolate Reductase: Improving Docking Enrichment Using Physics-Based Methods , 2005, Journal of biomolecular screening.

[46]  W. V. van Gunsteren,et al.  A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations , 2001 .

[47]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[48]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[49]  S. Sorbi,et al.  5-HT2A receptor gene polymorphisms in anorexia nervosa and bulimia nervosa , 1999, Neuroscience Letters.

[50]  H. Senderowitz,et al.  G Protein-Coupled Receptors: target-based in silico screening. , 2009, Current pharmaceutical design.

[51]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[52]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[53]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[54]  B. Roth,et al.  Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo , 2011, Journal of Pharmacology and Experimental Therapeutics.

[55]  R. Friesner,et al.  High‐resolution prediction of protein helix positions and orientations , 2004, Proteins.

[56]  Didier Rognan,et al.  A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.

[57]  D. Gloriam,et al.  Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. , 2009, Journal of medicinal chemistry.

[58]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[59]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[60]  George A. Kaminski,et al.  Force Field Validation Using Protein Side Chain Prediction , 2002 .

[61]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[62]  C. Vaillancourt,et al.  The 5-HT 2A serotonin receptor enhances cell viability, affects cell cycle progression and activates MEK-ERK1/2 and JAK2-STAT3 signalling pathways in human choriocarcinoma cell lines. , 2010, Placenta.

[63]  Gerhard Klebe,et al.  Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.

[64]  Ian T. Crosby,et al.  Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[65]  I. Sora,et al.  Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. , 2009, Neoplasia.

[66]  P. Salmi,et al.  Evidence for functional interactions between 5-HT1A and 5-HT2A receptors in rat thermoregulatory mechanisms. , 1998, Pharmacology & toxicology.

[67]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[68]  M. Rashid,et al.  Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. , 2004, Pharmacology & therapeutics.

[69]  P. Cowen,et al.  Slow wave sleep in humans: Role of 5-HT2A and 5-HT2C receptors , 1994, Neuropharmacology.

[70]  R. Glennon,et al.  Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands. , 2002, Current topics in medicinal chemistry.

[71]  B. Honig,et al.  A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.

[72]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[73]  P. Wild,et al.  Serotonin promotes tumor growth in human hepatocellular cancer , 2010, Hepatology.

[74]  H Weinstein,et al.  Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor , 1996, The Journal of Biological Chemistry.